Continuous Versus Bolus Infusion of Doxorubicin in Children With ALL: Long-term Cardiac Outcomes
about
The tell-tale heart: molecular and cellular responses to childhood anthracycline exposureEarly transcriptional alteration of histone deacetylases in a murine model of doxorubicin-induced cardiomyopathy.Cardiovascular disease in adult survivors of childhood cancer.Managing chemotherapy-related cardiotoxicity in survivors of childhood cancers.Long-term complications of therapeutic exposures in childhood: lessons learned from childhood cancer survivors.Intensified Chemotherapy With Dexrazoxane Cardioprotection in Newly Diagnosed Nonmetastatic Osteosarcoma: A Report From the Children's Oncology Group.Doxorubicin induced heart failure: Phenotype and molecular mechanisms.Anthracycline Chemotherapy and Cardiotoxicity.An expert opinion on pharmacologic approaches to reducing the cardiotoxicity of childhood acute lymphoblastic leukemia therapies.Treatment-related cardiotoxicity in survivors of childhood cancer.Heart transplantation in pediatric cardiomyopathies.Anthracycline-induced cardiotoxicity: a review of pathophysiology, diagnosis, and treatment.Cardiotoxicity of anticancer treatments.Heart failure and chemotherapeutic agents.Cardiac complications in childhood cancer survivors treated with anthracyclines.Preventing pediatric cardiomyopathy: a 2015 outlook.Cardiac Complications of Cancer Therapy: Pathophysiology, Identification, Prevention, Treatment, and Future Directions.Prevention of cardiotoxicity among survivors of childhood cancer.Late Cardiotoxicity: Issues for Childhood Cancer Survivors.Managing anthracycline-induced cardiotoxicity: beginning with the end in mind.Autophagy and mitophagy in the context of doxorubicin-induced cardiotoxicity.Chemotherapy-induced cardiotoxicity in children.Cardiotoxicity of cancer chemotherapy: identification, prevention and treatment.Cardiotoxicity in childhood cancer survivors: a problem with long-term consequences in need of early detection and prevention.Cardiovascular Complications of Cancer Therapy: Best Practices in Diagnosis, Prevention, and Management: Part 1.The duration of anthracycline infusion should be at least one hour in children with cancer: A clinical practice guideline.Anthracycline cardiotoxicity: the importance of horizontally integrating pre-clinical and clinical research.Anthracycline-induced cardiotoxicity in patients with paediatric bone sarcoma and soft tissue sarcoma.Antineoplastic Drug-Induced Cardiotoxicity: A Redox Perspective.Synergistic Effect of Endogenous and Exogenous Aldehydes on Doxorubicin Toxicity in Yeast.Trial watch: Immunogenic cell death induction by anticancer chemotherapeutics
P2860
Q26823592-4805E2E4-51E8-44EF-B361-542DE3394B6BQ33853732-74AB2EC0-75CC-4F0E-8095-085B220F5B93Q34042984-40A58A28-D3A3-431F-9F09-E2CB7A49554BQ35562745-03600A3B-675C-44E4-B213-EAF1540DBD9DQ36425784-9068F6BB-5791-4F87-B6B5-07782842ED63Q36653789-D65ECE7D-625E-408B-8449-E7E68149A133Q36912561-EEF4A44E-DFF2-4F5C-9051-1377DEF605A2Q37694541-459B6E1F-D98E-4F22-90DA-C1FBCA997F29Q38109236-24BD9ED8-6370-4FE2-91D2-757C9B364C96Q38156036-47F3F0E1-6DFE-4D15-8006-8600E696986DQ38161524-12D67F6D-6B59-4737-ABD3-0200E53D4CB9Q38205702-D8629DCC-0D4A-4414-AD0E-8A5BFCD91080Q38473331-501946E5-9BEB-4F6B-A8A8-A54CE1CBAA10Q38559133-99DC69BC-369E-40CF-B209-F07B7F569F74Q38588167-C4FA8575-9C37-43B4-96F4-7611219962F8Q38662111-64C2815C-D08D-4C25-ACB9-44B194C90287Q38735433-72598A24-5523-4D92-850B-BFE97194E96EQ38824644-6829FFBB-C18C-4DBC-B27C-F664ECDCA011Q38845457-734D619E-98D9-45B8-B45A-EC32BC3ED0FBQ38977933-512C5E13-B6E1-4B69-988E-741CDAE6429FQ39264180-4563F763-55E9-4A3A-9C8C-044635D8D39BQ39415815-B454B920-2FBE-4228-B3D4-9186B1E68EB3Q41704131-4DBDF037-8279-4F41-BE1F-051429D8854AQ43983538-6067BC95-FA29-49F6-B689-F2D76F20C146Q45073135-0F40E04D-37BE-45DF-B4B5-79C081460DE7Q48114515-F45BDF39-F350-4FBB-881B-928025D06119Q49617830-91436D84-AA31-477B-BBD7-D503FEF69E14Q50509868-D27DCD97-8BDE-4B1C-8C51-41735427813BQ51760757-0E0C1A8E-752A-4FD0-842B-2655DA914ABCQ55555497-DE26B8CB-5378-4E8B-9FA2-B35B7BA95F14Q56594845-6B2D3C7D-7332-4940-AD4A-FEDB736B70F8
P2860
Continuous Versus Bolus Infusion of Doxorubicin in Children With ALL: Long-term Cardiac Outcomes
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年学术文章
@wuu
2012年学术文章
@zh-cn
2012年学术文章
@zh-hans
2012年学术文章
@zh-my
2012年学术文章
@zh-sg
2012年學術文章
@yue
2012年學術文章
@zh
2012年學術文章
@zh-hant
name
Continuous Versus Bolus Infusi ...... LL: Long-term Cardiac Outcomes
@ast
Continuous Versus Bolus Infusi ...... LL: Long-term Cardiac Outcomes
@en
type
label
Continuous Versus Bolus Infusi ...... LL: Long-term Cardiac Outcomes
@ast
Continuous Versus Bolus Infusi ...... LL: Long-term Cardiac Outcomes
@en
prefLabel
Continuous Versus Bolus Infusi ...... LL: Long-term Cardiac Outcomes
@ast
Continuous Versus Bolus Infusi ...... LL: Long-term Cardiac Outcomes
@en
P2093
P2860
P356
P1433
P1476
Continuous Versus Bolus Infusi ...... LL: Long-term Cardiac Outcomes
@en
P2093
Barbara L Asselin
Bruno Michon
Caroline Laverdière
Dana-Farber Cancer Institute Acute Lymphoblastic Leukemia Consortium
Donna S Neuberg
Eric Larsen
Jacqueline M Henkel
Laura L Cushman
Lewis B Silverman
Luis A Clavell
P2860
P304
P356
10.1542/PEDS.2012-0727
P407
P577
2012-11-19T00:00:00Z